Prioritization of Peak’s ADC cancer therapeutic platform technology and Akari’s PAS-nomacopan for Geographic Atrophy, a disabling ophthalmic disease Akari Therapeutics (AKTX) announces leadership ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback